Effect of Octreotide on Saliva

Duke University

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: Octreotide 1 MG/ML

Study type

Interventional

Funder types

Other

Identifiers

NCT05340192

Pro00100579

Details and patient eligibility

About

The purpose of this study is to determine the effect of Octreotide on saliva enzymes. The study team hypothesizes that Octreotide will decrease the levels of certain proteins, specifically the metalloproteinase family.

Full description

This is a healthy volunteer pilot study. The purpose of this study is to determine the effect of a drug, Octreotide, on saliva enzymes in order to see if this drug can help prevent pharyngo-cutaneous fistulas (an abnormal tissue connection in the pharynx) in patients undergoing laryngectomy.

Enrollment

4 patients

Sex

All

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy adults between the ages of 18-40 years old
Healthy volunteer who is willing to undergo research activities
Healthy volunteer with no self-report of disease, oral symptoms or lesions, or cold or flu like symptoms that would affect the reflective measurements in the oral cavity
Ability to understand and the willingness to sign a written informed consent document

Exclusion criteria

Pregnant or nursing women
Children under the age of 18 or adults over 40
Complaint of oral symptoms (self-reported)
Medical condition affecting saliva (e.g. Sjogren's)
History of head/neck radiation
Medication that might affect saliva (e.g. Proton Pump Inhibitors)
Known allergy to Octreotide
Non-English speaking
Diabetes, gallbladder disease, heart disease, high blood pressure, a heart rhythm disorder, thyroid problems, pancreatitis, kidney disease, or liver disease (self-reported)